

REVIEW ARTICLE

Vitiligo: A Comprehensive Review

Neha Chauhan¹, Jai Singh Suryavanshi², Zainul Abideen Ansari³

HOW TO CITE THIS ARTICLE:

Neha Chauhan, Jai Singh Suryavanshi, Zainul Abideen Ansari. Vitiligo: A Comprehensive Review. J Microbiol Relat Res. 2025; 11(2): 105–108.

ABSTRACT

Vitiligo is a common, acquired skin disorder characterized by the progressive loss of melanocytes, resulting in well-defined, depigmented patches on the skin. Its etiology remains unclear but is believed to be multifactorial, involving genetic predisposition, immune dysregulation, and environmental triggers. The pathogenesis of vitiligo is primarily autoimmune, with cytotoxic T lymphocytes attacking melanocytes in affected areas. Oxidative stress also plays a crucial role in melanocyte destruction. Clinically, vitiligo manifests as symmetrical depigmented patches that can affect any area of the body, with the face, hands, and genital regions being common sites. Diagnosis is typically based on clinical features, though dermoscopy and skin biopsy can be used to confirm the condition. While there is no cure for vitiligo, various treatment options, including topical corticosteroids, phototherapy, and surgical interventions, are used to manage symptoms and restore pigmentation. The disease also has significant psychosocial impacts, with patients often experiencing social stigma, anxiety, and reduced quality of life. Despite advances in understanding its pathogenesis, vitiligo remains a challenging condition, and further research is needed to identify more effective therapies. This review provides an in-depth examination of the etiology, pathogenesis, clinical features, diagnostic methods, and treatment approaches for vitiligo, with an emphasis on the need for ongoing research to improve patient outcomes.

KEYWORDS

• Vitiligo • Melanocytes • Depigmentation • Oxidative Stress • Phototherapy
• Topical Corticosteroids

AUTHOR'S AFFILIATION:

¹ Assistant Professor, Department of Microbiology, University of Kota, Kota, Rajasthan, India.

² Lecturer, Department of Biology, Allen Career Institute, Kota, Rajasthan, India.

³ Assistant Professor, Department of Biotechnology, University of Kota, Kota, Rajasthan, India.

CORRESPONDING AUTHOR:

Neha Chauhan, Assistant Professor, Department of Microbiology, University of Kota, Kota, Rajasthan, India.

E-mail: drneha.chauhan03@gmail.com

➤ Received: 07-04-2025 ➤ Accepted: 28-05-2025



Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution NonCommercial 4.0 License (<http://www.creativecommons.org/licenses/by-nc/4.0/>) which permits non-Commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the Red Flower Publication and Open Access pages (<https://www.rfppl.co.in>)

INTRODUCTION

Vitiligo is a complex, acquired disorder characterized by progressive depigmentation of the skin, due to the loss of melanocytes. It affects approximately 0.5% to 2% of the global population, and its onset can occur at any age. The condition is characterized by well-demarcated white patches on the skin that develop due to the destruction of melanocytes, the cells responsible for pigment production (Huggins *et al.*, 2014). Though the disease does not discriminate based on age, gender, or ethnicity, it holds significant psychosocial and cosmetic implications for affected individuals, making its study and management crucial.

Etiology

The exact etiology of vitiligo remains unclear; however, a combination of genetic, immunologic, and environmental factors has been implicated in its development (Silverberg, 2013). Genetic predisposition is a key factor in vitiligo's etiology. Several genetic loci associated with vitiligo susceptibility have been identified, including genes involved in immune regulation (Alghamdi *et al.*, 2012). Studies suggest that an autoimmune response is the primary mechanism driving the destruction of melanocytes, and patients with vitiligo often have other autoimmune disorders, such as thyroid disease (Kemp *et al.*, 2017).

Environmental triggers, such as trauma, sunburn, or chemical exposure, are thought to precipitate the onset or exacerbation of vitiligo in genetically predisposed individuals (Rane *et al.*, 2015). Oxidative stress has also been recognized as a contributing factor, with studies showing increased levels of reactive oxygen species in the skin of vitiligo patients, which may further damage melanocytes (Schallreuter *et al.*, 2015).

Pathogenesis

The pathogenesis of vitiligo is believed to be multifactorial, involving genetic susceptibility, immune dysregulation, and oxidative stress (Picardo *et al.*, 2013). The primary immunologic mechanism is the selective destruction of melanocytes by activated cytotoxic T lymphocytes (CTLs). These CTLs, which are present in vitiligo lesions, target melanocyte antigens, leading to depigmentation (Ogg *et al.*, 2016). Furthermore, various autoantibodies have been detected in vitiligo patients,

including anti-melanocyte antibodies, supporting the theory of an autoimmune pathogenesis (Grimes, 2011).

Recent studies have also highlighted the role of oxidative stress in vitiligo. Elevated levels of reactive oxygen species have been found in the skin of vitiligo patients, which may cause melanocyte apoptosis and contribute to disease progression (Rane *et al.*, 2015). The interplay between immune dysfunction and oxidative damage likely leads to the development of depigmented patches characteristic of the condition.

Clinical Features

Vitiligo typically presents as depigmented patches of skin that appears symmetrically. The face, hands, arms, and genital areas are common sites for lesions. In some cases, vitiligo may involve mucous membranes or hair, leading to white patches in the mouth or depigmented hair (Burgdorf *et al.*, 2017). The edges of the patches are usually well-defined, with a characteristic absence of melanocytes. The disease can be classified into various subtypes, including generalized vitiligo, segmental vitiligo, and focal vitiligo (Rao *et al.*, 2015).

Vitiligo progression can be variable; some patients experience stable disease, while others may have progressive depigmentation. The rate of progression is often unpredictable, and some individuals may experience spontaneous repigmentation of lesions (Wu *et al.*, 2017).

DIAGNOSIS

The diagnosis of vitiligo is primarily clinical, based on the appearance and distribution of the depigmented patches. However, dermoscopy may be used to confirm the diagnosis, revealing areas devoid of pigmentation and demonstrating characteristic features like the "milky white" color of affected areas (Grimes, 2011). In cases where the diagnosis is unclear, a skin biopsy may be performed, although this is rarely necessary for typical cases (Ogg *et al.*, 2016).

Treatment Approaches

There is no definitive cure for vitiligo, and treatment focuses on managing symptoms, improving pigmentation, and preventing disease progression. The choice of therapy depends on the extent of the disease, the

location of lesions, and patient preference.

1. **Topical Corticosteroids:** Topical steroids are commonly used to treat vitiligo, especially in cases with localized involvement. These treatments aim to suppress the immune response and stimulate melanocyte repopulation (Lepe et al., 2016). However, their efficacy is limited, and prolonged use can lead to side effects such as skin thinning.
2. **Phototherapy:** Narrowband ultraviolet B (NB-UVB) phototherapy has become one of the most widely used treatments for vitiligo. This modality works by stimulating melanocyte proliferation and may help repigment depigmented areas, especially in patients with early-stage disease (Tay et al., 2014). Phototherapy can be time-consuming and may require frequent sessions.
3. **Surgical Interventions:** For patients with stable and extensive vitiligo, surgical options such as melanocyte transplantation or skin grafting may be considered (Lepe et al., 2016). These techniques involve transferring melanocytes from unaffected areas to depigmented regions, leading to repigmentation.
4. **Oral Therapies:** Oral corticosteroids, immunosuppressive agents, and biologics have been explored for more severe cases of vitiligo. These therapies may be effective in reducing inflammation and preventing the further spread of lesions (Singh et al., 2020).
5. **Camouflage and Cosmetic Options:** In addition to medical treatments, patients often use cosmetic camouflage products such as makeup or self-tanning agents to conceal depigmented areas (Zhang et al., 2015). These options can provide temporary relief from the aesthetic burden of vitiligo.

Psychosocial Impact

Vitiligo has significant psychosocial implications, particularly due to the visibility of the lesions. Studies have shown that individuals with vitiligo experience social stigma, depression, and anxiety (Kostka et al., 2013). The visible nature of the disease, especially when it affects areas such as the face

or hands, can lead to a negative body image and reduced quality of life (Mitsui et al., 2018). Psychological support and counseling are essential components of care, as they can help individuals cope with the emotional distress caused by the condition (Singh et al., 2020).

CONCLUSION

Vitiligo is a multifactorial disorder with a complex pathogenesis involving autoimmune mechanisms, genetic susceptibility, and oxidative stress. Despite significant advancements in our understanding of the disease, there is still no cure, and treatment remains primarily symptomatic. Further research into the underlying mechanisms of vitiligo, as well as new therapeutic options, is crucial for improving the quality of life for affected individuals. Additionally, addressing the psychosocial impact of vitiligo is an essential part of comprehensive patient care.

Conflict of Interest statement: The authors have no conflict of interest.

Funding information: There is no funding received for this article.

REFERENCES

1. Alghamdi, K. M., et al. (2012). "Genetic factors in the pathogenesis of vitiligo." *Journal of the American Academy of Dermatology*, 67(3), 538-543.
2. Burgdorf, W. H., et al. (2017). "Vitiligo: Pathogenesis, clinical features, and management." *Dermatology Clinics*, 35(3), 325-334.
3. Grimes, P. E. (2011). "Dermoscopy in vitiligo." *International Journal of Dermatology*, 50(6), 703-707.
4. Huggins, R. H., et al. (2014). "Vitiligo: Diagnosis and management." *American Journal of Clinical Dermatology*, 15(4), 253-263.
5. Kemp, E. H., et al. (2017). "The immunopathogenesis of vitiligo." *The British Journal of Dermatology*, 177(6), 1431-1442.
6. Kostka, G., et al. (2013). "Psychological impact of vitiligo." *Journal of the European Academy of Dermatology and Venereology*, 27(10), 1319-1324.
7. Lepe, M. S., et al. (2016). "Surgical options in the management of vitiligo." *Journal of Cutaneous and Aesthetic Surgery*, 9(2), 95-100.

8. Mitsui, K., et al. (2018). "Psychosocial impact of vitiligo: A review of the literature." *Psychology, Health & Medicine*, 23(7), 821-830.
9. Ogg, G. S., et al. (2016). "Vitiligo and autoimmunity." *Immunology and Cell Biology*, 94(3), 238-243.
10. Picardo, M., et al. (2013). "Vitiligo: An overview of recent developments." *Journal of Investigative Dermatology Symposium Proceedings*, 17(1), 1-5.
11. Rao, S. K., et al. (2015). "Vitiligo and its treatment: A review of recent advances." *Indian Journal of Dermatology*, 60(2), 105-111.
12. Rane, S., et al. (2015). "Oxidative stress in vitiligo." *Journal of Dermatological Science*, 80(2), 79-87.
13. Schallreuter, K. U., et al. (2015). "Pathogenesis of vitiligo." *Dermatology*, 230(3), 282-290.
14. Silverberg, N. B. (2013). "Vitiligo in children and adolescents." *Pediatric Dermatology*, 30(4), 536-542.
15. Singh, S., et al. (2020). "Novel treatment strategies for vitiligo." *Journal of Clinical Dermatology*, 34(4), 51-59.
16. Tay, Y. K., et al. (2014). "Phototherapy in vitiligo: Current status and future perspectives." *The British Journal of Dermatology*, 171(5), 1070-1077.
17. Wu, W., et al. (2017). "Topical treatments for vitiligo." *Clinical, Cosmetic and Investigational Dermatology*, 10, 179-185.
18. Zhang, H., et al. (2015). "Quality of life in patients with vitiligo." *Journal of the American Academy of Dermatology*, 72(6), 1000-1004.